TREOSULFAN, FLUDARABINE AND ALEMTUZUMAB CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY: UK EXPERIENCE

被引：0
|
作者：
Slatter, M. [1 ]
Rao, K. [2 ]
Nademi, Z. [1 ]
Chiesa, R. [2 ]
Amrolia, P. [2 ]
Flood, T. [1 ]
Abinun, M. [1 ]
Cant, A. [1 ]
Hambleton, S. [1 ]
Allwood, Z. [2 ]
Skinner, R. [1 ]
Samarasinghe, S. [1 ]
Nikolajeva, O. [2 ]
Qasim, W. [2 ]
Gaspar, H. [2 ]
Gennery, A. [1 ]
Veys, P. [2 ]
机构：
[1] Newcastle Tyne NHS Fdn Trust, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[2] Great Ormond St Hosp NHS Trust, London, England
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-O082
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [41] High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation
    Glowka, Franciszek K.
    Romanski, Michal
    Wachowiak, Jacek
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (10) : 1275 - 1295
  • [42] Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
    Casper, Jochen
    Wolff, Daniel
    Knauf, Wolfgang
    Blau, Igor W.
    Ruutu, Tapani
    Volin, Liisa
    Wandt, Hannes
    Schaefer-Eckart, Kerstin
    Holowiecki, Jerzy
    Giebel, Sebastian
    Aschan, Johan
    Zander, Axel R.
    Kroeger, Nicolaus
    Hilgendorf, Inken
    Baumgart, Joachim
    Mylius, Heidrun A.
    Pichlmeier, Uwe
    Freund, Mathias
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3344 - 3351
  • [43] THIOTEPA-TREOSULFAN-FLUDARABINE (TTF) AS CONDITIONING REGIMEN IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) FOR MYELOFIBROSIS
    Canale, Filippo Antonio
    Porto, Gaetana
    Verduci, Chiara
    Celentano, Maria
    Loteta, Barbara
    Pugliese, Marta
    Naso, Virginia
    Moscato, Tiziana
    Irrera, Giuseppe
    Console, Giuseppe
    Ferreri, Anna
    Picardi, Alessandra
    Martino, Massimo
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 496 - 497
  • [44] Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation
    I. W. Blau
    Martin Schmidt-Hieber
    N. Leschinger
    H. Göldner
    W. Knauf
    W. Hopfenmüller
    E. Thiel
    O. Blau
    Annals of Hematology, 2007, 86 : 583 - 589
  • [45] Allogeneic blood stem cell transplantation in patients with hematologic diseases after conditioning with treosulfan and fludarabine
    Casper, J
    Wilhelm, S
    Steiner, B
    Wolff, D
    Grobe, N
    Haehling, D
    Hartung, G
    Hilgendorf, I
    Lueck, A
    Junghanss, C
    Kahl, C
    Pichlmeier, U
    Freund, M
    BLOOD, 2005, 106 (11) : 770A - 770A
  • [46] Allogeneic hematopoietic stem cell transplantation after Treosulfan/Fludarabine conditioning in high-risk patients with hematologic malignancies. Dose escalation of Treosulfan.
    Jochen, C
    Blau, W
    Volin, L
    Ruutu, T
    Wandt, H
    Schaefer-Eckart, K
    Holowiecki, J
    Giebel, S
    Aschan, J
    Zander, AR
    Kroeger, N
    Freund, M
    Knauf, WU
    BLOOD, 2003, 102 (11) : 467A - 467A
  • [47] HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY IMMUNODEFICIENCY DISEASES: SINGLE CENTRE EXPERIENCE
    El-Sherif, Nayera
    Ali, Heba G. A.
    Makkeyah, Sara
    Sayed, Safa
    Radwan, Nesrine
    ElGhoneimy, Dalia
    Ebeid, Fatma S. E.
    Gouda, Sally
    BONE MARROW TRANSPLANTATION, 2024, 59 : 409 - 409
  • [48] Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients
    Baronciani, Donatella
    Rambaldi, Alessandro
    Iori, Anna Paola
    Di Bartolomeo, Paolo
    Pilo, Federica
    Pettinau, Martina
    Depau, Cristina
    Mico, Caterina
    Santarone, Stella
    Angelucci, Emanuele
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (09) : 717 - 720
  • [49] Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
    Nemecek, Eneida R.
    Guthrie, Katherine A.
    Sorror, Mohamed L.
    Wood, Brent L.
    Doney, Kristine C.
    Hilger, Ralf A.
    Scott, Bart L.
    Kovacsovics, Tibor J.
    Maziarz, Richard T.
    Woolfrey, Ann E.
    Bedalov, Antonio
    Sanders, Jean E.
    Pagel, John M.
    Sickle, Eileen J.
    Witherspoon, Robert
    Flowers, Mary E.
    Appelbaum, Frederick R.
    Deeg, H. Joachim
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (03) : 341 - 350
  • [50] Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation (SCT) in patients with AML and MDS not eligible for standard myeloablative conditioning: the role of treosulfan dose
    Shimoni, A.
    Peccatori, J.
    Shem-Tov, N.
    Lo Russo, A.
    Yerushalmi, R.
    Bernardi, M.
    Nagler, A.
    Ciceri, F.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S220 - S220
12345